DALIDUO

This brand name is authorized in South Africa

Active ingredients

The drug DALIDUO contains a combination of these active pharmaceutical ingredients (APIs):

1 Rilpivirine UNII 212WAX8KDD - RILPIVIRINE HYDROCHLORIDE

Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ. Read about Rilpivirine

2 Dolutegravir UNII 1Q1V9V5WYQ - DOLUTEGRAVIR SODIUM

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Read about Dolutegravir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
DALIDUO Film-coated tablet	Health Products Regulatory Authority (ZA)	MPI, Generic

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AR21	Dolutegravir and rilpivirine	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR21

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ZA	Health Products Regulatory Authority	Identifier(s): 55/20.2.8/0301